Research shows reducing SIRPα slows tumor growth and delays brain metastases — Evidence Review

Researchers at Wake Forest University School of Medicine have identified SIRPα as a potential driver of triple-negative breast cancer (TNBC) metastasis to the brain and immune evasion. Related studies generally support the importance of tumor-microenvironment interactions and immune regulation in breast cancer brain metastases.

• The new study’s findings align with existing research which highlights the complexity of brain metastasis in TNBC, emphasizing both the adaptation of cancer cells to the brain microenvironment and their interactions with immune defenses such as microglia 1 2 3 4.
• Prior research has demonstrated that targeting the CD47-SIRPα signaling pathway can enhance anti-tumor immune responses, particularly through macrophage and myeloid cell activity, supporting the rationale for targeting SIRPα in cancer therapy 6 7 8 9 10.
• While most previous studies have focused on the role of SIRPα in immune cells, the current research uniquely suggests that SIRPα also acts within cancer cells themselves to promote metastasis, representing a novel therapeutic target and expanding on earlier work 6 7 8 9 10.

Study Overview and Key Findings

Brain metastasis in triple-negative breast cancer (TNBC) remains a significant clinical challenge due to limited treatment options and poor outcomes. This new preclinical investigation addresses a crucial gap by identifying the protein SIRPα as a key factor not only in immune regulation but also in cancer-cell-intrinsic processes that enable TNBC cells to invade the brain and evade local immune defenses. The study provides evidence that SIRPα modulates both tumor metabolism and the brain microenvironment, with potential implications for developing new therapeutic approaches.

Property	Value
Study Year	2026
Organization	Wake Forest University School of Medicine
Journal Name	Neuro-Oncology
Authors	Yu-Ting Tsai, Jessica D Mackert, Adam Wilson, Mitra Kooshki, Valerie Payne, Jamie J Sagastume, Ashley Szymonski, Brian Westwood, Lance D Miller, Pierre L Triozzi, Dawen Zhao, Linda Metheny-Barlow, Masaki Terabe, Katherine L Cook, Glenn J Lesser, David R Soto-Pantoja
Population	Triple-negative breast cancer cells
Methods	Animal Study
Outcome	SIRPα levels, tumor growth, brain metastases
Results	Reducing SIRPα slowed tumor growth and delayed brain metastases.

Literature Review: Related Studies

To contextualize these findings, we searched the Consensus database, which includes over 200 million research papers. The following queries were used to identify relevant studies:

1. breast cancer brain metastases mechanisms
2. SIRPα tumor growth reduction effects
3. aggressive breast cancer treatment outcomes

Topic	Key Findings
How do breast cancer cells metastasize to the brain and adapt to its microenvironment?	- Brain metastases involve complex tumor-cell adaptation to the brain’s unique microenvironment, requiring both genetic predisposition and interaction with resident brain cells such as astrocytes and microglia 1 2 3 4. - TNBC and HER2+ breast cancers show distinct patterns of brain colonization and tumor architecture, which affect immune cell engagement and may influence therapeutic response 2.
What is the role of SIRPα and CD47-SIRPα signaling in tumor progression and immune evasion?	- SIRPα, particularly through the CD47-SIRPα pathway, acts as an immune checkpoint that inhibits macrophage-mediated phagocytosis, allowing tumor cells to evade immune surveillance; targeting this pathway enhances anti-tumor immunity in preclinical studies 6 7 8 9 10. - Anti-SIRPα antibodies and genetic silencing of SIRPα in engineered immune cells improve tumor clearance and promote cytotoxic T-cell infiltration in animal models 7 8 9 10.
How do current treatments and clinical outcomes for aggressive breast cancer subtypes, like TNBC, compare to novel approaches targeting immune regulation?	- TNBC is associated with poorer prognosis and higher rates of brain metastases compared to other breast cancer subtypes; existing treatments have limited efficacy against brain metastases and often lack specificity for intracerebral tumors 1 4 5 12 15. - Platinum-based chemotherapy and targeted therapies can improve outcomes in early TNBC, but new strategies—such as modulating immune checkpoints like SIRPα—are being investigated to address brain metastasis 13 10.

How do breast cancer cells metastasize to the brain and adapt to its microenvironment?

Studies consistently describe brain metastasis as a multistep process in which tumor cells must not only breach the blood-brain barrier but also adapt to the brain’s specialized environment, involving close interplay with resident cells like astrocytes and microglia. The new study’s focus on SIRPα’s role in both tumor cells and the immune microenvironment adds a novel dimension to this area of research, highlighting a mechanism by which TNBC cells may manipulate their surroundings for survival and growth in the brain.

• The formation of brain metastases requires tumor cells to adapt to the brain’s distinctive microenvironment, involving interactions with brain-resident immune cells 1 2 3 4.
• TNBC and HER2+ breast cancers display different colonization patterns and engage immune cells differently, which may impact disease progression and treatment response 2.
• The brain’s immune-resident microglia and astrocytes play crucial roles in either supporting or resisting metastatic growth, depending on the tumor’s molecular features 2 3.
• The new study’s identification of SIRPα as a factor in tumor cell adaptation and immune evasion directly builds on this body of literature, providing a new target for intervention.

What is the role of SIRPα and CD47-SIRPα signaling in tumor progression and immune evasion?

Previous research has established the CD47-SIRPα axis as a critical pathway by which tumors evade immune destruction, primarily by inhibiting phagocytosis by macrophages. The present study supports and extends these findings by demonstrating that SIRPα also acts within breast cancer cells to promote brain metastasis, suggesting that therapeutic targeting of SIRPα may offer dual benefits: modulating both tumor-intrinsic properties and anti-tumor immune responses.

• Blocking CD47-SIRPα signaling enhances phagocytosis and immune-mediated tumor clearance in animal models, providing a rationale for its therapeutic targeting 6 7 8 9 10.
• Anti-SIRPα antibodies, SIRPα-deficient macrophages, and silencing SIRPα in engineered immune cells all show improved tumor control and enhanced T-cell infiltration 7 8 10.
• Prior studies have focused mainly on the role of SIRPα in immune cells, whereas the new study identifies a cancer-cell-intrinsic function of SIRPα in metastasis 6 7 8 9 10.
• These findings suggest that future therapies may benefit from targeting SIRPα in both the tumor and the immune compartments.

How do current treatments and clinical outcomes for aggressive breast cancer subtypes, like TNBC, compare to novel approaches targeting immune regulation?

TNBC is recognized for its aggressive clinical course and high propensity for brain metastasis, with limited effectiveness of conventional therapies against metastatic disease in the brain. The literature underscores the need for new therapeutic strategies, such as immune checkpoint modulation, that could improve outcomes for these patients. The current study’s exploration of SIRPα as a therapeutic target fits within this broader context of seeking innovative approaches beyond cytotoxic chemotherapy.

• TNBC is associated with higher rates of brain metastases and poorer outcomes compared to other breast cancer subtypes, and current treatments are often inadequate for intracerebral disease 1 4 5 12 15.
• Existing therapeutic strategies, including platinum-based chemotherapy, have modest benefits but are limited by toxicity and lack of specificity for brain metastases 13 5.
• Immune-based therapies targeting molecules like SIRPα are being actively investigated as potential ways to enhance anti-tumor immunity and improve survival 10.
• The novel findings of SIRPα’s tumor-intrinsic role may expand the therapeutic landscape for TNBC patients at high risk for brain involvement.

Future Research Questions

Further research is needed to determine whether targeting SIRPα can be safely and effectively translated into clinical practice, and to clarify the molecular pathways involved in TNBC brain metastasis. Key unanswered questions include the safety and efficacy of SIRPα-targeted therapies in humans, the interplay between tumor cells and the brain microenvironment, and how these approaches could be integrated with existing treatments.

Research Question	Relevance
Can SIRPα inhibition safely prevent or delay brain metastases in TNBC patients?	Determining clinical safety and efficacy is critical for translating preclinical findings to patient care, especially given the aggressive nature of TNBC and the current lack of effective options 1 4 5 13.
What are the long-term effects of targeting SIRPα in breast cancer therapy?	Understanding potential adverse effects and durability of response is essential for future clinical application, especially as SIRPα is involved in immune regulation throughout the body 6 7 8 10.
How does SIRPα modulation impact the brain microenvironment and immune response?	Mechanistic studies are needed to clarify how SIRPα affects both cancer cell behavior and the function of brain-resident immune cells, which may inform combination therapies 2 3 4.
Can SIRPα inhibition enhance the effectiveness of current immunotherapies in TNBC brain metastases?	Investigating combination strategies may provide synergistic benefits and improve outcomes for patients with brain metastases, where immune checkpoint blockade alone has had limited success 7 8 10.
Are there biomarkers that predict response to SIRPα-targeted therapy in breast cancer?	Identifying predictive biomarkers would help tailor treatments to patients most likely to benefit, optimizing therapeutic outcomes and minimizing unnecessary exposure 1 2 4 5.